Research programme: companion diagnostics - Astellas/Ventana Medical Systems

Drug Profile

Research programme: companion diagnostics - Astellas/Ventana Medical Systems

Alternative Names: ASP 5878 companion diagnostic

Latest Information Update: 19 May 2015

Price : $50

At a glance

  • Originator Ventana Medical Systems
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 15 Apr 2015 Early research in Solid tumours (Diagnosis) in USA (unspecified route)
  • 15 Apr 2015 Ventana Medical Systems is collaborating with Astellas Pharma for the development of companion diagnostics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top